Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 19,265 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Ventures V. L.P. 5Am sold 19,265 shares of the stock in a transaction on Friday, June 27th. The stock was sold at an average price of $6.91, for a total transaction of $133,121.15. Following the sale, the insider directly owned 1,113,092 shares of the company's stock, valued at $7,691,465.72. This represents a 1.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

Entrada Therapeutics Price Performance

TRDA stock traded up $0.39 during mid-day trading on Tuesday, reaching $7.11. The company had a trading volume of 205,752 shares, compared to its average volume of 134,114. The company has a market capitalization of $269.82 million, a price-to-earnings ratio of 8.30 and a beta of -0.11. Entrada Therapeutics, Inc. has a 52 week low of $6.53 and a 52 week high of $21.79. The stock has a 50 day simple moving average of $8.01 and a two-hundred day simple moving average of $10.88.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.36. Entrada Therapeutics had a net margin of 14.39% and a return on equity of 5.84%. The business had revenue of $8.75 million during the quarter, compared to the consensus estimate of $10.98 million. On average, equities analysts predict that Entrada Therapeutics, Inc. will post 1.12 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on TRDA. Wall Street Zen raised shares of Entrada Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research report on Tuesday, May 20th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $25.67.

Hedge Funds Weigh In On Entrada Therapeutics

Large investors have recently modified their holdings of the stock. BNP Paribas Financial Markets acquired a new position in shares of Entrada Therapeutics in the fourth quarter valued at approximately $57,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Entrada Therapeutics by 152.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,750 shares of the company's stock valued at $618,000 after purchasing an additional 21,594 shares in the last quarter. Deutsche Bank AG lifted its holdings in shares of Entrada Therapeutics by 55.5% during the 4th quarter. Deutsche Bank AG now owns 21,740 shares of the company's stock worth $376,000 after acquiring an additional 7,757 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Entrada Therapeutics during the fourth quarter worth $36,000. Finally, Ameriprise Financial Inc. grew its position in Entrada Therapeutics by 6.6% in the fourth quarter. Ameriprise Financial Inc. now owns 40,624 shares of the company's stock valued at $702,000 after acquiring an additional 2,517 shares during the last quarter. 86.39% of the stock is owned by institutional investors.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.